Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Dynamic hyperinflation in patients with COPD

INTRODUCTION

Exercise-induced air trapping is referred to as dynamic hyperinflation. Patients with chronic obstructive pulmonary disease (COPD) are particularly susceptible to dynamic hyperinflation. Common questions include:

  • What causes dynamic hyperinflation?
  • What are its clinical manifestations?
  • How is it diagnosed?
  • What is the treatment?

The pathophysiology, clinical presentation, diagnosis, and treatment of dynamic hyperinflation in patients with COPD are reviewed here. The diagnosis and treatment of COPD are discussed separately. (See "Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging" and "Management of stable chronic obstructive pulmonary disease".)

PATHOPHYSIOLOGY

Lung volumes remain stable when the tidal volume is completely exhaled prior to the initiation of the next breath. Tidal volume increases during exercise (figure 1). Therefore, maintenance of stable lung volumes requires that expiratory muscles be recruited to elevate pleural and alveolar pressure, increase expiratory flow, and force the increased tidal volume to be completely exhaled prior to the next breath.

Hyperinflation — Hyperinflation exists when the end-expiratory lung volume is increased, usually due to an airflow limitation. Hyperinflation acts as a compensatory mechanism. At higher lung volumes, there is decreased airway resistance and increased elastic recoil, resulting in improved expiratory flow. Two types of hyperinflation can be distinguished: static and dynamic.

                    

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Aug 2014. | This topic last updated: Jun 6, 2013.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. MacNee W. Pathophysiology of acute exacerbations of chronic obstructive pulmonary disease. In: Acute exacerbations of chronic obstructive pulmonary disease. Lung Biology in Health and Disease, vol 183, Siafakas NM, Anthonisen NR, Georgopoulos D (Eds), 2004. p.29.
  2. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343:269.
  3. Milic-Emili J. Dynamic pulmonary hyperinflation and intrinsic PEEP: consequences and management in patients with chronic obstructive pulmonary disease. Recenti Prog Med 1990; 81:733.
  4. Johnson BD, Beck KC, Zeballos RJ, Weisman IM. Advances in pulmonary laboratory testing. Chest 1999; 116:1377.
  5. Decramer M. Respiratory muscle interaction during acute and chronic hyperinflation. Monaldi Arch Chest Dis 1993; 48:483.
  6. Mahler DA. Mechanisms and measurement of dyspnea in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3:234.
  7. Hannink JD, van Helvoort HA, Dekhuijzen PN, Heijdra YF. Dynamic hyperinflation during daily activities: does COPD global initiative for chronic obstructive lung disease stage matter? Chest 2010; 137:1116.
  8. Calverley PM, Koulouris NG. Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology. Eur Respir J 2005; 25:186.
  9. Younes M, Kivinen G. Respiratory mechanics and breathing pattern during and following maximal exercise. J Appl Physiol Respir Environ Exerc Physiol 1984; 57:1773.
  10. Johnson BD, Reddan WG, Seow KC, Dempsey JA. Mechanical constraints on exercise hyperpnea in a fit aging population. Am Rev Respir Dis 1991; 143:968.
  11. Johnson BD, Saupe KW, Dempsey JA. Mechanical constraints on exercise hyperpnea in endurance athletes. J Appl Physiol (1985) 1992; 73:874.
  12. Babb TG, Viggiano R, Hurley B, et al. Effect of mild-to-moderate airflow limitation on exercise capacity. J Appl Physiol (1985) 1991; 70:223.
  13. Johnson BD, Scanlon PD, Beck KC. Regulation of ventilatory capacity during exercise in asthmatics. J Appl Physiol (1985) 1995; 79:892.
  14. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160:542.
  15. Gelb AF, Taylor CF, Cassino C, et al. Tiotropium induced bronchodilation and protection from dynamic hyperinflation is independent of extent of emphysema in COPD. Pulm Pharmacol Ther 2009; 22:237.
  16. O'Donnell DE, Flüge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23:832.
  17. Bellamy D, Hutchison DC. The effects of salbutamol aerosol on lung function in patients with pulmonary emphysema. Br J Dis Chest 1981; 75:190.
  18. Rabe KF. Improving dyspnea in chronic obstructive pulmonary disease: optimal treatment strategies. Proc Am Thorac Soc 2006; 3:270.
  19. O'Donnell DE, Sciurba F, Celli B, et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 2006; 130:647.
  20. Stav D, Raz M. Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study. Chest 2009; 136:381.
  21. O'Donnell DE, Voduc N, Fitzpatrick M, Webb KA. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004; 24:86.
  22. Casaburi R, Porszasz J. Reduction of hyperinflation by pharmacologic and other interventions. Proc Am Thorac Soc 2006; 3:185.
  23. Somfay A, Porszasz J, Lee SM, Casaburi R. Dose-response effect of oxygen on hyperinflation and exercise endurance in nonhypoxaemic COPD patients. Eur Respir J 2001; 18:77.
  24. Stevenson NJ, Calverley PM. Effect of oxygen on recovery from maximal exercise in patients with chronic obstructive pulmonary disease. Thorax 2004; 59:668.
  25. Eves ND, Petersen SR, Haykowsky MJ, et al. Helium-hyperoxia, exercise, and respiratory mechanics in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174:763.
  26. Porszasz J, Emtner M, Goto S, et al. Exercise training decreases ventilatory requirements and exercise-induced hyperinflation at submaximal intensities in patients with COPD. Chest 2005; 128:2025.
  27. Chrystyn H, Mulley BA, Peake MD. Dose response relation to oral theophylline in severe chronic obstructive airways disease. BMJ 1988; 297:1506.
  28. Martinez FJ, de Oca MM, Whyte RI, et al. Lung-volume reduction improves dyspnea, dynamic hyperinflation, and respiratory muscle function. Am J Respir Crit Care Med 1997; 155:1984.
  29. Laghi F, Jubran A, Topeli A, et al. Effect of lung volume reduction surgery on neuromechanical coupling of the diaphragm. Am J Respir Crit Care Med 1998; 157:475.
  30. O'Donnell DE, Webb KA, Bertley JC, et al. Mechanisms of relief of exertional breathlessness following unilateral bullectomy and lung volume reduction surgery in emphysema. Chest 1996; 110:18.